Beta-catenin:T-cell factor family protein-protein interface (Beta-catenin:TCF interface)

The Beta-catenin:T-cell factor (TCF) family protein-protein interface is the terminal effector complex of the canonical Wnt signaling pathway. Under physiological conditions, Wnt signaling triggers the nuclear translocation of beta-catenin, which then displaces transcriptional repressors and binds to TCF/LEF (Lymphoid Enhancer-binding Factor) proteins to activate target genes such as MYC and CCND1 (UniProt P35222; PubMed 28677118). This interaction is frequently hyperactivated in human cancers, particularly colorectal cancer, where mutations in the APC tumor suppressor or beta-catenin itself lead to uncontrolled cell proliferation (PubMed 30104919). As a therapeutic target, the interface is considered challenging due to its large, flat surface area, yet several small-molecule inhibitors like LF3 and PNU-74654 have been developed to competitively inhibit this binding (PubMed 25103560). Clinical development of inhibitors targeting this transcriptional complex, such as PRI-724, focuses on modulating the output of the Wnt pathway to treat refractory malignancies and fibrotic diseases (PubMed 27515922). However, the essential role of Wnt signaling in maintaining tissue homeostasis, particularly in the intestinal epithelium and bone, presents significant safety concerns regarding systemic toxicity (PubMed 28230130).

Other names

Beta-catenin:TCF/LEF complexCTNNB1:TCF interactionWnt/beta-catenin transcription complexBeta-catenin:TCF4 interface

Inhibition of the protein-protein interaction between nuclear beta-catenin and T-cell factor (TCF)/lymphoid enhancer-binding factor (LEF) transcription factors to block the recruitment of the transcriptional machinery to Wnt-responsive elements.